Clinicopathological and Prognostic Value of Gastric Carcinoma Highly Expressed Transcript 1 in Cancer: A Meta-Analysis

Zhou, Xi; Fan, Yanghua; He, Yu; Mou, Anna; Wang, Fu; Liu, Yong; Wu, Zhen

doi:10.1155/2020/6341093

Cited by 4 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have confirmed that lncRNAs are involved in tumorigenesis, as well as in the treatment and prognosis of tumors (17,(31)(32)(33). For example, Xu et al found that up-regulation of lncRNA-CCHE1 could promote gastric cancer cell proliferative ability and colony formation, inhibiting cell apoptosis; however, low-expression of lncRNA-CCHE1 had the opposite effect.…”

Section: Discussionmentioning

confidence: 93%

Cervical carcinoma high-expressed long non-coding RNA 1 promotes papillary thyroid carcinoma cell proliferation and invasion

Shi¹,

Ling²,

Zhang³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Studies have shown that cervical carcinoma high-expressed long non-coding RNA 1 (lncRNA-CCHE1) may promote tumor development by regulating tumor migration and invasion in a variety of cancers; yet, the role of lncRNA-CCHE1 in papillary thyroid carcinoma (PTC) remains unclear. The purpose of this study was to explore the mechanism of lncRNA-CCHE1 in PTC. Methods:The expression of lncRNA-CCHE1 in 51 PTC carcinoma tissues and normal adjacent tissues was measured using real-time quantitative polymerase chain reaction (RT-qPCR). Cell Counting Kit-8 (CCK8), plate cloning assay, transwell assay, and flow cytometry were used to analyze the effect of lncRNA-CCHE1 on PTC cell proliferation, invasion, and apoptosis in vitro.Results: A higher expression of lncRNA-CCHE1 was found in PTC tissues than in adjacent tissues. High expression of lncRNA-CCHE1 was positively correlated with the number of tumors, extra-glandular invasion, and tumor stage. In addition, the down-regulation of lncRNA-CCHE1 reduced the proliferation and invasion of PTC cell lines and promoted cell apoptosis, while its up-regulation caused the opposite effect. These effects were regulated via the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/ MAPK) pathway. Conclusions:The lncRNA-CCHE1 is closely related to PTC progression and may be used as a potential biomarker for early diagnosis and treatment of PTC.

show abstract

Section: Discussionmentioning

confidence: 93%

Cervical carcinoma high-expressed long non-coding RNA 1 promotes papillary thyroid carcinoma cell proliferation and invasion

Shi¹,

Ling²,

Zhang³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…APC Min/+ mice are an ideal mouse model for studying the mechanism of CRC [37]. Previously, studies have found that lncRNA can participate in the occurrence and development of tumors through various molecular mechanisms and can serve as targets for cancer diagnosis, treatment, and prognosis prediction [38].…”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA THOR, a novel target biomolecule, is involved in the progression of colorectal cancer

Zhou

Ouyang

et al. 2023

Preprint

View full text Add to dashboard Cite

THOR is a long noncoding RNA that is highly conserved and highly expressed in a variety of human tumor cells. A large number of studies show that THOR is deeply involved in the occurrence and development of a variety of cancers. However, the role and potential molecular mechanisms of THOR in the initiation and progression of CRC have not been fully elucidated. Here, we demonstrate that THOR is crucial for the occurrence of CRC; it interacts with IGF2BP1 to regulate the downstream Wnt/β-catenin signaling pathway. To clarify the contribution of THOR in the occurrence and development of CRC, we established THOR-deficient APCMin/+ mice and human colorectal cancer cells (SW480) using CRISPR/Cas9 technology. The results showed that the body weight and survival rate of THOR-deficient APCMin/+ mice increased; hyperlipidemia in elderly mice was alleviated, and changes in intestinal structure were attenuated. THOR knockout inhibited the growth, proliferation, and migration of SW480 cells. Downstream regulator genes, including c-MYC, APC, SOX9, Wnt1, CDH1, Axin1, Axin2, LEF 1, were knocked down with THOR knockout. In summary, our results indicate that THOR knockout inhibits the growth and migration of CRC cells and that THOR is a promising prognostic indicator for CRC patients. Moreover, the THOR-IGF2BP1-Wnt/β-catenin axis may be a potential therapeutic target for CRC, providing new insights into the important role of lncRNAs in cancer.

show abstract

“…However, the diversified results, the heterogeneity of lncRNAs biology and prognosis, as well as the presence of different treatment options make the clinical decision-making process highly varied. Thus, a series of systematic reviews and meta-analyses have been conducted to provide further evidences on the relationship between variants of dysregulated lncRNAs and prognosis of cancer ( Chen C et al, 2018 ; Quan et al, 2018 ; Tian et al, 2018 ; Zhang S et al, 2020 ; Yang et al, 2020 ; Zhou et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

The Value of Dysregulated LncRNAs on Clinicopathology and Survival in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Background: There is growing evidence that a number of lncRNAs are involved in the pathogenesis of non-small-cell lung cancer (NSCLC). However, studies on lncRNA expression in NSCLC patients are far from conclusive. Therefore, we performed a systematic review of such studies to collect and examine the evidence on the potential role of lncRNAs in the development of NSCLC.Methods: We systematically searched seven literature databases to identify all published studies that evaluated the expression of one or more lncRNAs in human samples with NSCLC (cases) and without NSCLC (controls) from January 1, 1995 to May 24, 2021. Quality assessment of studies was conducted by using the “Quality in Prognosis Studies” (QUIPS) tool, and the heterogeneity across studies was analyzed with the I-squared statistic and chi-square-based Q-tests. Either fixed or random-effect meta-analysis was performed to summarize effect size to investigate the association between lncRNA expression and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and clinicopathological features. The R statistical software program was used to conduct standard meta-analysis.Results: We finally obtained 48 studies with 5,211 patients included in this review after screening. Among the 48 lncRNAs, 38 lncRNAs were consistently upregulated, and 10 were deregulated in patients with NSCLC compared with the control groups. The upregulated lncRNAs were positively associated with histological type: study number (n) = 18, odds ratio (OR) = 0.78, 95% CI: 0.65–0.95 and OR = 1.30, 95% CI: 1.08–1.57, p < 0.01; TNM stages: n = 20, OR = 0.41, 95% CI: 0.29–0.57 and OR = 2.44, 95% CI: 1.73–3.44, p < 0.01; lymph node metastasis: n = 29, OR = 0.49, 95% CI: 0.34–0.71 and OR = 2.04, 95% CI: 1.40–2.96, p < 0.01; differentiation grade: n = 6, OR = 0.61, 95% CI: 0.38–0.99 and OR = 1.63, 95% CI: 1.01–2.64, p < 0.01; distant metastasis: n = 9, OR = 0.37, 95% CI: 0.26–0.53 and OR = 2.72, 95% CI: 1.90–3.90, p < 0.01; tumor size: n = 16, OR = 0.52, 95% CI: 0.43–0.64 and OR = 1.92, 95% CI: 1.57–2.34, p < 0.01; and overall survival [n = 38, hazard ratio (HR) = 1.79, 95% CI = 1.59–2.02, p < 0.01]. Especially, five upregulated lncRNAs (linc01234, ZEB1-AS1, linc00152, PVT1, and BANCR) were closely associated with TNM Ⅲa stage (n = 5, OR = 4.07, 95% CI: 2.63–6.28, p < 0.01). However, 10 deregulated lncRNAs were not significantly associated with the pathogenesis and overall survival in NSCLC in the meta-analysis (p ≥ 0.05).Conclusion: This systematic review suggests that the upregulated lncRNAs could serve as biomarkers for predicting promising prognosis of NSCLC. The prognostic value of downregulated lncRNA in NSCLC needs to be further explored.Systematic Review Registration: (http://www.crd.york.ac.uk/PROSPERO).identifier CRD42021240635.

show abstract

Clinicopathological and Prognostic Value of Gastric Carcinoma Highly Expressed Transcript 1 in Cancer: A Meta-Analysis

Cited by 4 publications

References 41 publications

Cervical carcinoma high-expressed long non-coding RNA 1 promotes papillary thyroid carcinoma cell proliferation and invasion

Cervical carcinoma high-expressed long non-coding RNA 1 promotes papillary thyroid carcinoma cell proliferation and invasion

Long noncoding RNA THOR, a novel target biomolecule, is involved in the progression of colorectal cancer

The Value of Dysregulated LncRNAs on Clinicopathology and Survival in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About